Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 67.36 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; purified talc; pregelatinised maize starch; lactose monohydrate; hypromellose; triethyl citrate; polysorbate 80; isopropyl alcohol; hypromellose phthalate; magnesium stearate; dichloromethane; methanol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; iron oxide yellow; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid; indigo carmine aluminium lake; ethanol; strong ammonia solution; iron oxide black - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 33.68 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; lactose monohydrate; croscarmellose sodium; dichloromethane; polysorbate 80; hypromellose; pregelatinised maize starch; magnesium stearate; methanol; purified talc; isopropyl alcohol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; ethanol; strong ammonia solution; iron oxide black; indigo carmine; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; indigo carmine; purified talc; hypromellose; gelatin; titanium dioxide; sucrose; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; triethyl citrate; titanium dioxide; sucrose; indigo carmine; hypromellose phthalate; purified talc; hypromellose; iron oxide yellow; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Israeli - Kiingereza - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Israeli - Kiingereza - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride -